隧道纳米管为牛病毒性腹泻病毒传播提供新途径

Tunneling nanotubes provide a new route for bovine viral diarrhea virus spreading.

作者信息Jiying Yin, Zehui Zhou, Ning He, Hongming Zhou, Xiaoqun Liu, Yixing Zhao, Longge Zhao, Jiating Zhang, Yanan Zhu, Ying Zong, Naichao Diao, Kun Shi, Rui Du
PMID41142567
发布时间2025-10-10
DOI10.3389/fvets.2025.1667394

实验完整度

包含transwell共培养、药物干预、免疫荧光、扫描电镜、iSTORM和活细胞动态成像等多层级实验,并进行了结构验证和功能验证,证据链完整。

主要模型

MDBK细胞 BVDV NADL株

重点核对

transwell实验使用0.4μm和12μm孔径聚碳酸酯膜,验证细胞间直接接触传播 药物干预浓度:paclitaxel(10 nM)、nocodazole(50 ng/ml)、cytochalasin D(50 μg/ml)、latrunculin A(10 nM)、carbenoxolone(1 mM) 中和抗体存在下,BVDV仍可通过细胞间接触传播 iSTORM和活细胞成像证实BVDV颗粒通过TNTs转移 统计使用one-way ANOVA和Bonferroni检验,P<0.05

摘要

Introduction: Bovine viral diarrhea virus (BVDV) is one of the major pathogens currently endangering the world's cattle industry. It poses serious difficulties in prevention and treatment because it can infect cattle of all ages and the specific mechanism of its cell-to-cell transmission has not yet been fully clarified. Tunneling nanotubes (TNTs) are F-actin-rich tubules that connect to the cytoplasm of nearby cells. They have been found to play an important role in the transmission of several viruses, but studies on BVDV in TNTs have not been reported.Methods: Firstly, the transwell assay was employed to investigate the transmission routes of BVDV and its capacity to propagate via intercellular junctional structures in the presence of neutralizing antibodies. Secondly, preliminary characterization of these junctional structures was conducted through pharmacological intervention experiments using the microtubule stabilizer paclitaxel, the microtubule disruptor nocodazole, the F-actin disruptors cyclosporine D and spongiosin A, and the gap junction blocker glycine. Subsequently, we validated the composition, spatial positioning, microscopic morphology, and generation characteristics of intercellular junctional structures following BVDV infection. Finally, iSTORM and live-cell fluorescence dynamic imaging techniques, we observed the transmission of BVDV viral particles through TNTs.Results: Transwell assays demonstrated that BVDV can be transmitted via direct intercellular contact, a mode of transmission unaffected by neutralizing antibodies. Pharmacological studies revealed that only the F-actin disruptors spongin A and cell relaxin D inhibited the formation of this structure, preliminarily identifying it as a tunnel nanotube. Validation experiments confirmed that the composition, spatial orientation, microstructure, and formation direction of this connecting structure align with tunneling nanotube characteristics, further substantiating its identity as TNTs. iSTORM and live-cell fluorescence dynamic imaging revealed that BVDV particles can traverse TNTs to complete intercellular infection.Discussion: We first report that BVDV can induce the formation of tunneling nanotubes and exploits this route to spread to uninfected cells. Our data highlight a previously unknown route of BVDV spreading, which could have significant implications for celler transmission and immune evasion.

实验结论

提炼研究问题、关键发现与证据,快速把握文章的核心贡献。

研究问题
BVDV能否通过隧道纳米管(TNTs)进行细胞间传播?
核心机制
BVDV感染MDBK细胞后诱导F-actin丰富的TNTs形成,病毒颗粒沿TNTs传播至邻近细胞,从而逃避中和抗体的作用。
主要证据
transwell实验显示中和抗体存在下BVDV仍可传播;药物干预证实TNTs由F-actin构成;iSTORM和活细胞成像直接观察到病毒颗粒在TNTs内移动。
研究意义
首次揭示TNTs介导BVDV传播的新机制,为理解BVDV免疫逃逸和持续感染提供新见解,对未来疫苗设计和防控策略有潜在意义。

研究路径

按研究推进顺序梳理实验设计、验证步骤与关键观察。

1

验证BVDV传播依赖细胞间直接接触

确定BVDV是否通过细胞间直接接触传播,而非仅通过游离病毒颗粒。

使用transwell共培养系统,采用0.4μm和12μm孔径膜分离感染细胞和靶细胞,并在中和抗体存在下观察感染情况。

2

鉴定细胞间连接结构为TNTs

通过药物干预和形态学验证,确认BVDV诱导的细胞间连接结构是隧道纳米管。

使用paclitaxel、nocodazole、cytochalasin D、latrunculin A和carbenoxolone处理感染细胞,观察TNTs形成;并通过免疫荧光、扫描电镜和3D重建分析结构特征。

3

验证BVDV促进TNTs形成

确定BVDV感染是否显著增加MDBK细胞间TNTs的数量。

用MOI 1 BVDV感染MDBK细胞,通过光镜和免疫荧光计数TNTs,并测量长度分布。

4

确认TNTs生成方向

验证TNTs是否优先从感染细胞延伸至未感染细胞。

用DiO和DiL分别标记感染和未感染细胞,共培养后观察TNTs延伸方向。

5

观察病毒颗粒在TNTs内的存在

利用超分辨显微镜iSTORM直接观察BVDV颗粒是否存在于TNTs内。

BVDV感染细胞固定后,使用BVDV E2抗体和F-actin抗体标记,iSTORM成像观察病毒颗粒。

6

动态观测BVDV沿TNTs传播

实时观测BVDV病毒颗粒是否通过TNTs从感染细胞转移到未感染细胞。

用DiL标记BVDV,DiO标记细胞膜,活细胞成像系统每30分钟采集图像,观察病毒移动。

研究方法

按研究目的归类文中使用的方法,便于定位所需技术。

验证细胞间传播方式
观察病毒颗粒定位
动态追踪病毒传播

产品清单

实验环节名称品牌货号
DMEM培养基Gibco--
胎牛血清Gibco--
BVDV E2单克隆抗体Veterinary Medical Research & Development# 348
山羊抗小鼠IgG(H+L)-FITC偶联二抗abcam# ab6785
F-actin抗体Biossbs-1571R
TRITC标记的鬼笔环肽YEASEN40734ES75
细胞松弛素DYEASEN53215ES03
紫杉醇YEASEN53530ES10
诺考达唑YEASEN51301ES08
拉特曲林AShanghai yuanye Bio-Technology76343-93-6
甘珀酸MACKLIN5697-56-3
DiO细胞膜荧光探针BeyotimeC1038
DiL细胞膜荧光探针BeyotimeC1036
Transwell聚碳酸酯膜嵌入物Corning--
扫描电子显微镜HitachiSU3800
随机光学重建显微镜INVIEW3CM
Hoechst 33342活细胞染色液----

关键环节

汇总复现实验时建议重点确认的条件及原文阅读提示。

环节核对要点
细胞培养与病毒感染
MDBK细胞(Bio-68289)培养条件:DMEM+10%FBS,37°C,5% CO2;BVDV NADL株(ATCC VR-534)感染MOI。
阅读提示:Methods 2.1 Cells and virus
transwell传播实验
transwell膜孔径(0.4μm和12μm)、中和抗体稀释度(1:400)、共培养时间(24h)。
阅读提示:Methods 2.4 Transwell coculture assay; Results 3.1
药物干预
药物种类及浓度:paclitaxel (10 nM)、nocodazole (50 ng/ml)、cytochalasin D (50 μg/ml)、latrunculin A (10 nM)、carbenoxolone (1 mM)。
阅读提示:Methods 2.1; Results 3.2
TNTs形态与定位观察
免疫荧光染色(BVDV E2、F-actin)、扫描电镜样品制备(戊二醛固定、乙醇梯度脱水、临界点干燥、Pt溅射)、3D重建。
阅读提示:Methods 2.3, 2.5; Results 3.3
TNTs方向性实验
DiO和DiL标记,感染与未感染细胞共培养比例(1:1)和时间(24h)。
阅读提示:Methods 2.6; Results 3.4
iSTORM观察
固定条件(3% PFA+0.1%戊二醛)、抗体浓度(anti-BVDV E2 1:100, anti-F-actin 1:50)、二抗(CF568 1:200, Alexa Fluor 647 1:400)。
阅读提示:Methods 2.7; Results 3.5
活细胞动态成像
DiL标记病毒浓度(250 μM)、染色时间(90min)、DiO染色30min、Hoechst染色20min、成像间隔(30min)、迁移率计算。
阅读提示:Methods 2.8; Results 3.6
统计分析
数据表示(均值±标准误)、统计方法(one-way ANOVA、Bonferroni事后检验)、显著性水平(*P<0.05, **P<0.01, ***P<0.001)
阅读提示:Methods 2.9